GENERATE BIOMEDICINES INC (GENB) Forecast, Price Target & Analyst Ratings

NASDAQ:GENB • US3709201004

Current stock price

13.15 USD
+0.52 (+4.12%)
At close:
13.3 USD
+0.15 (+1.14%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GENERATE BIOMEDICINES INC (GENB).

Forecast Snapshot

Consensus Price Target

Price Target
$21.93
+ 66.77% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$21.93
Upside
+ 66.77%
From current price of $13.15 to mean target of $21.93, Based on 8 analyst forecasts
Low
$16.16
Median
$22.44
High
$27.30

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for GENB. The average price target is 21.93 USD. This implies a price increase of 66.77% is expected in the next year compared to the current price of 13.15.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GENB Current Analyst RatingGENB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

GENB Historical Analyst RatingsGENB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
GENB was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about GENB.
GENB was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-13HC Wainwright & Co.Initiate Buy
2026-03-24Cantor FitzgeraldInitiate Overweight
2026-03-24GuggenheimInitiate Buy
2026-03-24Goldman SachsInitiate Buy
2026-03-24Morgan StanleyInitiate Overweight
2026-03-24Piper SandlerInitiate Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
GENB revenue by date.GENB revenue by date.
20M32M
60.00%		30.281M
-5.37%		35.303M
16.58%		169.32M
379.62%		22.95M
-86.45%		166.46M
625.32%		455.23M
173.48%		782.54M
71.90%		1.265B
61.65%
EBITDA
YoY % growth
GENB ebitda by date.GENB ebitda by date.
-182M-222M
-21.98%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
GENB ebit by date.GENB ebit by date.
-197M-235M
-19.29%		N/AN/AN/A-401.88M-366.996M
8.68%		-144.789M
60.55%		96.951M
166.96%		498.93M
414.62%
Operating Margin
GENB operating margin by date.GENB operating margin by date.
-985.00%-734.38%N/AN/AN/A-1,751.11%-220.47%-31.81%12.39%39.44%
EPS
YoY % growth
GENB eps by date.GENB eps by date.
N/AN/A-2.22-2.22
-0.23%		-1.91
14.22%		N/AN/AN/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.51-0.49-0.53-0.55-0.55
-8.00%		-0.55
-10.88%		-0.55
-2.88%		-0.57
-2.78%
Revenue
Q2Q % growth		6.056M7.013M7.969M9.244M2.55M
-57.89%		3.315M
-52.73%		3.825M
-52.00%		4.504M
-51.28%
EBITDA
Q2Q % growth		-64.982M-66.005M-72.128M-75.701MN/AN/AN/AN/A
EBIT
Q2Q % growth		-60.945M-65.359M-70.737M-72.743M-71.91M
-17.99%		-73.44M
-12.36%		-72.42M
-2.38%		-74.121M
-1.89%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GENB Yearly Revenue VS EstimatesGENB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
GENB Yearly EPS VS EstimatesGENB Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 2028 -0.5 -1 -1.5 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

GENERATE BIOMEDICINES INC / GENB Forecast FAQ

What do analysts expect the price target to be for GENERATE BIOMEDICINES INC (GENB)?

8 analysts have analysed GENB and the average price target is 21.93 USD. This implies a price increase of 66.77% is expected in the next year compared to the current price of 13.15.